Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled date : 2021 - 06 - 07 save search
First Industrial Realty Trust To Participate In Nareit's REITweek: 2021 Investor Conference
Published: 2021-06-07 (Crawled : 22:00) - prnewswire.com
FR | $45.63 -0.96% 0.0% 2.1M
|
Finance
|
| O: 0.06%
H: 1.47%
C: 1.22%
trial conference
How Vault CDMS Streamlines Data Collection for Oncology Trials
Published: 2021-06-07 (Crawled : 20:00) - veeva.com
VEEV | $198.38 -0.58% 0.0% 730K
|
Technology Services
|
| O: 1.19%
H: 0.69%
C: -0.82%
trial
$ 246.02 Million growth expected in Global Industrial Biomass Boiler Market during 2021-2025 | Technavio
Published: 2021-06-07 (Crawled : 20:00) - prnewswire.com
BW | News | $0.9279 -4.18% 0.0% 1.1M
|
Electronic Technology
|
| O: 0.22%
H: 2.2%
C: 1.21%
growth trial
Oncology Trial Design and Study Build
Published: 2021-06-07 (Crawled : 19:00) - veeva.com
VEEV | $198.38 -0.58% 0.0% 730K
|
Technology Services
|
| O: 1.19%
H: 0.69%
C: -0.82%
trial designation
Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)
Published: 2021-06-07 (Crawled : 18:00) - biospace.com/
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: -0.12%
H: 4.21%
C: 2.01%
phase 2 clinical trials phase 2/3 phase 3 trial enroll
MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib
Published: 2021-06-07 (Crawled : 18:00) - biospace.com/
MEIP | $3.3 1.54% 1.52% 26K
|
Health Technology
|
| O: 0.67%
H: 5.52%
C: 4.01%
phase 2
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
Published: 2021-06-07 (Crawled : 18:00) - biospace.com/
KZIA | $0.379 9.47% 8.65% 300K
|
Health Technology
|
| O: -0.1%
H: 2.81%
C: 1.48%
cancer enroll paxalisib
Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021
Published: 2021-06-07 (Crawled : 17:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.06%
H: 1.26%
C: 0.72%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -0.36%
H: 0.85%
C: -1.03%
results cancer phase 3 trial
Medtronic Insertable Cardiac Monitor Detects Significantly Higher Rates of Atrial Fibrillation in Large and Small Vessel Stroke Patients Compared to Standard of Care
Published: 2021-06-07 (Crawled : 15:00) - biospace.com/
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: 0.44%
H: 0.6%
C: -0.35%
stroke trial
Clinical Catch-Up: June 1-6
Published: 2021-06-07 (Crawled : 15:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.02%
H: 0.19%
C: -0.7%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.32%
H: 0.85%
C: -0.06%
Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort
Published: 2021-06-07 (Crawled : 14:15) - adnas.com
APDN | $0.3396 0.59% 0.59% 85K
|
Commercial Services
|
| O: 3.45%
H: 4.67%
C: 4.5%
covid vaccine trial antibody covid-19
Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, P1, and B.1.526 Variants and Sets August 2021 Mink Challenge Trial Launch
Published: 2021-06-07 (Crawled : 14:00) - biospace.com/
APDN | $0.3396 0.59% 0.59% 85K
|
Commercial Services
|
| O: 3.45%
H: 4.67%
C: 4.5%
covid vaccine trial antibody
Rexford Industrial Announces $76.3 Million of Transaction Activity
Published: 2021-06-07 (Crawled : 13:15) - prnewswire.com
REXR | $42.74 -1.04% 0.0% 2.7M
|
Finance
|
| O: 0.41%
H: 1.84%
C: 1.68%
ford trial
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
Published: 2021-06-07 (Crawled : 13:00) - biospace.com/
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
|
| O: 4.85%
H: 0.46%
C: -1.36%
disease fda clinical hold
JJ Ruest, President and Chief Executive Officer, and Sean Finn, Executive Vice-President, Corporate Services and Chief Legal Officer, to address the UBS Global Industrials and Transportation Virtual Conference on June 8
Published: 2021-06-07 (Crawled : 12:15) - globenewswire.com
CNI | $127.65 0.39% 0.31% 720K
|
Transportation
|
| O: 0.36%
H: 0.0%
C: -1.71%
trial conference
Industrial Dispenser Market is projected to reach close to US$ 14 Bn by 2031-end: Persistence Market Research
Published: 2021-06-07 (Crawled : 12:00) - prnewswire.com
GGG | $88.38 0.33% 0.0% 490K
|
Producer Manufacturing
|
| O: -0.4%
H: 0.37%
C: -0.45%
NDSN 4 | $259.54 0.16% 0.16% 150K
|
Producer Manufacturing
|
| O: 0.09%
H: 0.15%
C: -0.81%
ce mark research trial
Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
DCTH | $4.87 3.73% 3.59% 300K
|
Health Technology
|
| O: 7.99%
H: 1.2%
C: -5.59%
positive results trial
Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
SRRK 4 | $13.85 -0.72% -0.72% 710K
|
Health Technology
|
| O: 0.15%
H: 8.24%
C: 6.74%
phase 2 research trial muscular atrophy
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
GLSI | $12.17 -5.59% -5.92% 31K
|
Health Technology
|
| O: 2.0%
H: 1.21%
C: -4.94%
treatment positive cancer breast cancer trial metastatic breast cancer
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
AUPH | $5.01 4.16% 3.99% 1.6M
|
Health Technology
|
| O: 1.76%
H: 2.36%
C: 1.42%
phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.